



Tuesday, 15 May 2018

Break
08:00 - 09:30

Foyer

Registration and Welcome Coffee

Plenary Session
09:30 - 10:00

Congress Hall

Welcome Address

CIMT President Christoph Huber

09:30 - 10:00

Plenary Session
10:00 - 11:30

Congress Hall

Cellular Therapy

New modes of T-cell cancer recognition by dissection of immunotherapy successes

10:00 - 10:30

Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom)

ADAPting to solid tumors, advances and challenges for TCR T-cell therapy

10:30 - 11:00

Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States)

TIL therapy in melanoma: history of clinical development, current status and plans for the future

11:00 - 11:30

Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center, Houston, United States)

Break
11:30 - 13:30

Foyer

Lunch

Corporate Supported Symposium
12:00 - 13:00

Congress Hall

"Immunooncology 2018 and beyond" supported by Bristol-Myers Squibb

Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Immunooncology from mono- to combination therapy - a clinical perspective	12:00 - 12:20
Speaker: Viktor Grünwald (Hanover, Germany)	
Resistance to Immunotherapy	12:20 - 12:40
Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg, Germany)	
Biomarkers in Immunooncology - can we predict the outcome of therapy?	12:40 - 13:00
Speaker: Andreas Jung (Ludwig-Maximilians-Universität, Munich, Germany)	
Plenary Session 13:30 - 15:00	Congress Hall
Counteracting Immune Escape	
TNFR family members and cancer immunotherapy: lessons from chronic infection	13:30 - 14:00
Speaker: Tania Watts (University of Toronto, Toronto, Canada)	
title of talk to be announced	14:00 - 14:30
Speaker: Melody Swartz (University of Chicago, Chicago, United States)	
Regulation of dendritic cells in tumors	14:30 - 15:00
Speaker: Jan P. Böttcher (Technical University Munich, Munich, Germany)	
Break 15:00 - 16:00	Foyer
Coffee Break	
Poster Session 15:00 - 18:00	East and West Foyers
Poster Session I	
Plenary Session 18:00 - 19:00	Congress Hall
Keynote Lecture	
Highly multiplex 2D and 3D imaging of the immune system and tumors	18:00 - 19:00
Speaker: Ronald Germain (NIAD, NIH, Bethesda, United States)	

Plenary Session
08:00 - 09:30

Congress Hall

Tumor Microenvironment

Potent and durable tumor immunity induced by ADU-S100, a first-in-class STING agonist **08:00 - 08:30**

Speaker: Andrea van Elsas (Aduro Biotech, Oss, Netherlands)

The Ying and Yang of TAM: Macrophages as effector cells for cytotoxic antibodies in vivo **08:30 - 09:00**

Speaker: Falk Nimmerjahn (Friedrich-Alexander-University, Erlangen, Germany)

Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells **09:00 - 09:30**

Speaker: Vincenzo Bronte (University of Verona, Verona, Italy)

Break
09:30 - 10:00

Foyer

Coffee Break

Short Talk Session
10:00 - 11:30

Gutenberg Hall

Short Talk Session I, II, III

Break
11:30 - 14:00

Foyer

Lunch

Plenary Session
12:00 - 13:30

Congress Hall

CAR T-Cell Therapy organized by CARAT

Chimeric antigen receptor T cells: advances in cellular engineering and clinical development **12:00 - 12:30**

Speaker: Bruce Levine (University of Pennsylvania, Philadelphia, United States)

title of talk to be determined **12:30 - 13:00**

Speaker: Martin Pule (University College London, London, United Kingdom)

Cell therapy between academic research and company driven drug development **13:00 - 13:30**

Speaker: Peter Borchmann (University Hospital of Cologne, Cologne, Germany)

Plenary Session
14:00 - 15:30

Congress Hall

Combination Therapies

Stromal Activation in Cancer Immunology and Immunotherapy Speaker: Shannon Turley (Genentech, San Francisco, United States)	14:00 - 14:30
Mechanistic insights into the immune adjuvant effect of radiotherapy Speaker: Sandra Demaria (Weill Cornell Medicine, New York, United States)	14:30 - 15:00
title of talk to be announced Speaker: Jack Pollard (Sanofi Oncology, Cambridge, United States)	15:00 - 15:30

Break
15:30 - 16:30

Foyer

Coffee Break

Poster Session
15:30 - 18:30

East and West Foyers

Poster Session II

CIMT Members Meeting
17:30 - 19:00

Dijon Room

General Members Assembly of the Association for Cancer Immunotherapy CIMT

19:30 - 24:00

Foyer

Social Event & Poster Award Ceremony

Plenary Session
08:30 - 10:00

Congress Hall

Immunoguiding

Chair: Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)
Chair: Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)

Reprogramming the tumor microenvironment for efficient cancer immunotherapy

08:30 - 09:00

Speaker: Günter J. Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Complement in cancer: untangling an intricate relationship

09:00 - 09:30

Speaker: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

Lung cancer evolution and immune escape

09:30 - 10:00

Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)

Break
10:00 - 10:30

Foyer

Coffee Break

Plenary Session
10:30 - 12:30

Congress Hall

Regulatory Research organized by CIMT-RRG and CARAT

Chair: Ulrich Kalinke (TWINCORE, Hanover, Germany)
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)

Chimeric antigen receptor (CAR) modified T cells - EU regulatory considerations

10:30 - 11:10

Speaker: Martina Schüssler-Lenz (Committee for Advanced Therapies (CAT), European Medicines Agency, London, United Kingdom)

Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles

11:10 - 11:50

Speaker: Bernd Schröder (Miltenyi Biotech, Teterow, Germany)

From Karl Landsteiner to CAR-T Cells: from processes to products and patients

11:50 - 12:30

Speaker: Martin Hildebrandt (Technical University Munich, Munich, Germany)

Short Talk Session
10:30 - 13:00

Gutenberg Hall

Short Talk Session IV, V, VI, VII

Break
13:00 - 14:00

Foyer

Lunch

Plenary Session
14:00 - 15:30

Congress Hall

Therapeutic Vaccination

Dendritic cell-based vaccination against cancer

14:00 - 14:30

Speaker: Jolanda de Vries (Radboud University, Nijmegen, Netherlands)

Therapeutic cancer vaccine for combination with immune checkpoint blockade therapy: formulation matters

14:30 - 15:00

Speaker: Yared Hailemichael (MD Anderson Cancer Center, Houston, United States)